SIGA Technologies

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.

Earnings data Q1 2024

SIGA anticipates strong oral TPOXX deliveries, declares special dividend

SIGA's Q1 2023 performance reflects strong revenue and a healthy cash balance, supported by significant upcoming oral TPOXX deliveries. The company's proactive approach to research and development, as well as its commitment to rewarding shareholders, positions it well for future growth. However, challenges in production scaling and regulatory processes require continued attention. Overall, SIGA remains focused on addressing emerging infectious diseases and bio-defense threats, presenting promising opportunities for expansion.

SIGA projects strong revenue growth, seeks new CEO amid opportunities

SIGA's Q2 2023 earnings call highlighted strong revenue expectations for the second half of 2023, driven by oral TPOXX deliveries and international sales. The company faces the challenge of CEO succession and operational complexities related to contracts and studies. However, opportunities for growth are evident in the PEP label expansion program, potential buybacks, and ongoing international sales growth.

SIGA targets $90-100 million pretax income in 2023, faces packaging challenges

SIGA's Q3 2023 earnings call highlighted the company's financial targets, updates on development programs, and the impact of outbreaks on public health. The call also addressed challenges related to packaging delays and inventory build, while emphasizing opportunities for incremental orders and international expansion.

SIGA reports robust earnings, plans for strategic growth initiatives

SIGA delivered impressive financial results, demonstrating strong growth and profitability in Q4 2023. The company's focus on innovation, government contracts, and strategic investments positions it well for future success. Despite challenges in a competitive market, SIGA's robust performance and strategic initiatives highlight its resilience and potential for sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

In the latest trading session, Siga Technologies Inc. (SIGA) closed at $8.34, marking a +1.34% move from the previous day.

Siga Technologies Inc. (SIGA) Increases Despite Market Slip: Here's What You Need to Know

Siga Technologies Inc. (SIGA) reachead $8.88 at the closing of the latest trading day, reflecting a +0.79% change compared to its last close.

Siga Technologies Inc. (SIGA) Advances While Market Declines: Some Information for Investors

Northern Trust

SEI Investments

SIGA, SEIC and NTRS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 12, 2024.

Best Momentum Stocks to Buy for April 12th

Ameri Holdings

Intrusion

Zuora

ZUO, INTZ, SIGA, ENVB and NTRS have been added to the Zacks Rank #1 (Strong Buy) List on April 12, 2024.

New Strong Buy Stocks for April 12th

SIGA and AZZ made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 12, 2024.

Best Value Stocks to Buy for April 12th

Adecoagro

Dell Technologies

DELL, AGRO and SIGA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 10, 2023.

Best Momentum Stocks to Buy for April 10th

StepStone Group

Weave Communications

DELL, WEAV, AGRO, SIGA and STEP have been added to the Zacks Rank #1 (Strong Buy) List on April 10, 2023.

New Strong Buy Stocks for April 10th

High Tide

Marathon Petroleum

HITI, MPC and SIGA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 2, 2023.

Best Momentum Stocks to Buy for April 2nd

Crescent Point Energy

Cytek Biosciences

Crexendo, Inc.

CXDO, HITI, SIGA, CPG and CTKB have been added to the Zacks Rank #1 (Strong Buy) List on April 2, 2023.

New Strong Buy Stocks for April 2nd

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious disease, announced today that it entered into an amendment to its international promotion agreement with Meridian Medical Technologies, Inc. (Meridian). Effective June 1, SIGA will drive international promotion activities for oral TPOXX® while maintaining its contractual relationship with Meridian to maintain continuity for key customer relationships.

SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX®

SIGA stock is setting new 52-week highs after a strong earnings report. The post-earnings rally is also supported by a special cash dividend of $0.60, going ex-dividend on 25 March.

Siga Technologies: Preparing For A Contingency If Tomorrow Comes

Siga Technologies (SIGA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Siga Technologies (SIGA) Rating Upgrade to Buy

SIGA Technologies, Inc. (SIGA) Q4 2023 Earnings Call Transcript

• Increased Product Sales to $131 Million in 2023 • Grew Pre-tax Operating Income to $84 Million in 2023 • Declared Today a Special Cash Dividend of $0.60 per Share • Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2023. “In 2023, SIGA had approximately $131 million in product revenues and approximately $84 million of pre-tax operating income,” stated Diem Nguyen, Chief Executive Officer.

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023

NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0.60 per share on the company's common stock. This represents an increase of $0.15 per share, or 33%, over the cash dividend paid in June 2023.

SIGA Declares Special Cash Dividend of $0.60 Per Share

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, March 12th, 2024. Participating in the call will be Dr. Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results

NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Diem Nguyen, Ph.D., will join the Company as chief executive officer (CEO), effective January 27, 2024, and will also be appointed to the Company's Board of Directors. SIGA's current CEO, Dr. Phil Gomez, will retire from SIGA on January 26, 2024.

SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer

SIGA Technologies delivered impressive net sales expectations for Q4 and is working to expand its treatment of human smallpox in new jurisdictions. The company has regulatory approvals for its oral antiviral drug Tpoxx and is exploring expanding its FDA label to include post-exposure prophylaxis against smallpox. SIGA stock has established significant agreements with government entities and international organizations to supply its Tpoxx product, which could drive net sales growth.

SIGA Technologies: Impressive Net Sales Guidance, FDA Approval, And Cheap

SIGA Technologies, Inc. (NASDAQ:SIGA ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Phillip Louis Gomez - Chief Executive Officer Dennis Hruby - Executive Vice President and Chief Scientific Officer Jay Varma - Executive Vice President and Chief Medical Officer Daniel Luckshire - Executive Vice President and Chief Financial Officer Conference Call Participants Pooya Hemami - Edison Group Paul Saunders - Hatch Capital Operator Welcome to the SIGA business update call. Before we turn the call over to SIGA Management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements.

SIGA Technologies, Inc. (SIGA) Q3 2023 Earnings Call Transcript

- In Third Quarter, SIGA Received U.S. Government Orders for Approximately $113 Million of Oral TPOXX and $25 Million of IV TPOXX® -

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023

NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, November 7th, 2023. Participating on the call will be Phil Gomez, Chief Executive Officer, Dennis Hruby, Chief Scientific Officer, Dr. Jay Varma, Chief Medical Officer and Daniel Luckshire, Chief Financial Officer.

SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the creation by the European Commission's DG HERA (Health Emergency Preparedness and Response Authority) of a joint procurement mechanism under which 13 participating countries from the European Union (EU) and the European Free Trade Association (EFTA) can efficiently order oral TPOXX. Based on commitments from EU member countries, it is currently anticipated that $18 million in approximate value of oral TPOXX will be initially ordered by EU countries under this mechanism within the next 60 days. Orders through the joint procurement mechanism will result in country-level procurement of oral TPOXX. Under the joint procurement mechanism, countries in the EU will acquire courses of oral TPOXX in the near term, and be able to efficiently order additional courses of oral TPOXX in the future as long as minimum quantity thresholds are met. Separately, as announced in September of 2022, the European Commission procured oral TPOXX through the funding of a direct purchase. Both transactions were coordinated by SIGA and its international promotion partner, Meridian Medical Technologies, LLC.

SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries

Duolingo

G-III Apparel Group

Lantronix

Virco Mfg.

We have narrowed our search to five Nasdaq Composite-listed stocks that have popped more than 10% in the past month. These are: VIRC, GIII, SIGA, DUOL, LTRX.

Top 5 High-Flying Nasdaq Stocks Defying Index's Recent Turmoil

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Jay K. Varma has joined SIGA as Executive Vice President and Chief Medical Officer (CMO). He will also continue to serve as a director of the SIGA Board of Directors.

SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer

SIGA Technologies, Inc. (NASDAQ:SIGA ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Phil Gomez - Chief Executive Officer Dennis Hruby - Chief Scientific Officer Dan Luckshire - Chief Financial Officer Conference Call Participants Pooya Hemami - Edison Group Scott Sibley - Equis Group Operator Welcome to the SIGA Business Update Call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements.

News for SIGA Technologies Stock (SIGA)